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ABSTRACT
Background: Chronic rhinosinusitis (CRS) and allergic rhinitis are associated with functional limitations, but these impacts are not known on a population
basis. Our objective was to epidemiologically determine functional limitations and workdays lost that are associated with CRS and allergic rhinitis in adults.
Methods: The Medical Expenditure Panel Survey for calendar year 2007 was examined to identify cases of CRS and allergic rhinitis. Functional limitation
variables for activity limitation, work limitation, social limitation, and cognitive limitation determined by the survey also were extracted. Using multivariate
models adjusting for age, gender, race, ethnicity, education level, insurance status, geographic region, as well as the Charlson comorbidity index, incremental
differences in workdays lost and these functional limitations were determined for patients with and without CRS and allergic rhinitis.
Results: Among 225.1 million adults, the prevalences of CRS and allergic rhinitis were 4.9  0.2% and 7.9  0.3%, respectively. Patients with CRS
demonstrated an incremental 1.04  0.3 workdays lost per year along with significant increased adjusted odds ratios for activity limitation (odds ratio, 1.54),
work limitation (1.50), and social limitation (1.49, all p  .005) but not cognitive limitation (1.05, p  .213). Patients with allergic rhinitis demonstrated an
incremental 0.60  0.45 workdays lost along with significant increased adjusted odds ratios for activity limitation (1.42), work limitation (1.43), social
limitation (1.47), and cognitive limitation (1.32, all p  .019).
Conclusions: Both CRS and allergic rhinitis impart significantly increased odds ratios for activity, work, and social limitations. Allergic rhinitis also carries
with it statistically significant odds of functional cognitive limitation. The total aggregate workdays missed in the United States may be estimated at 11.5
million workdays and 10.7 million workdays for CRS and allergic rhinitis, respectively.
(Am J Rhinol Allergy 26, 120–122, 2012; doi: 10.2500/ajra.2012.26.3752)
C
hronic rhinosinusitis (CRS) and allergic rhinitis (AR) are among
the most common and burdensome chronic conditions in the
United States. Recent data suggest that an estimated 11.1 million
Americans suffer from CRS each year, and AR affects an estimated
17.8 million Americans annually.1,2 The burden of these illnesses in
terms of direct costs to the health care system is tremendous.3–5
Reflective of their associated health care disease burdens, both CRS
and AR impart a substantial individual quality of life burden on
affected subjects.
Many studies have been conducted to examine the decreases in
quality of life experienced by patients suffering from CRS or AR.6–9
These have most commonly consisted of cohort studies often selected
from tertiary care medical centers and subspecialty rhinology prac-
tices. There are limited data regarding the overall quality of life
burdens from CRS and AR, particularly in a nonreferral and nonsur-
gical population. We sought to examine the quality of life burdens of
CRS and AR in terms of functional limitations on a national, epide-
miologic scale. This would provide national estimates of the patients’
burden with these illnesses, likely overcoming selection and ascer-
tainment biases that may be present in previous reports.
METHODS
The data source for this study consisted of the Medical Expenditure
Panel Survey (MEPS) for 2007 as administered by the Agency for
Healthcare Research and Quality under the U.S. Department of
Health and Human Services. The MEPS is an overlapping panel
design survey following a nationally representative sample of the U.S.
civilian, noninstitutionalized population over the course of 2 years.10
The MEPS household component contains detailed self-reported in-
formation on demographic and socioeconomic characteristics as well
as health conditions, insurance status, use of health care services
employment, and missed workdays. Data are obtained at the house-
hold level and completed by one household member, who may be a
proxy. Upon completion of the household MEPS component, a sam-
ple of medical providers are contacted by telephone to obtain sup-
plemental information regarding dates of provider visits, diagnoses
and procedure codes, charges and payments. These data are con-
tained in the medical provider component of the MEPS.
This study was reviewed by our hospital’s committee on clinical
investigations and designated as exempt from review. In accordance
with data access agreements, precautions were taken to avoid indi-
vidual patient identification. The 2007 household component of the
MEPS was merged with the 2007 medical provider component ac-
cording to the appropriate linkage variables in SPSS 17.0 (Chicago,
IL). Because patients may report more than one medical condition, up
to 34 medical condition variables were allowed per patient after the
data files were merged.
Next, patients were identified as suffering from CRS or AR by
examining the ICD9CODX data field for each listed medical condi-
tion. This field consists of the three-digit International Classification
of Diseases version 9 code for a given medical condition based on an
assessment of medical conditions recorded as verbatim text and then
coded by a professional coder. Patients for whom any one of the 34
medical condition codes corresponded to 473.x and 477.x were con-
sidered as having CRS or AR, respectively; the remaining patients
were considered as not reporting either of these two conditions.
Standard demographic information including age and gender dis-
tribution was compiled for those patients reporting and not reporting
AR. The additional demographic information extracted and com-
pared included race, ethnicity, level of education, insurance status,
geographic region, and marital status (Table 1). In addition, the
adaptation by D’Hoore et al11 of the Charlson comorbidity index was
calculated based on comorbid medical conditions for each subject.
This index adjusts for comorbidities that include myocardial infarc-
tion, congestive heart failure, peripheral vascular disease, dementia,
cerebral vascular disease, asthma, chronic obstructive pulmonary
disease, peptic ulcer disease, and liver disease, among others. It
allows patients to be compared with “like” patients with similar
comorbidities.
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Because the survey sample design of the MEPS survey includes
stratification, clustering, multiple stages of selection, and dispropor-
tionate sampling, statistical methods that take into account stratifica-
tion, clustering, and the sampling methods used in MEPS data col-
lection (i.e., the complex samples algorithm in SPSS) were used to
determine nationally representative means and SEs.10 Estimates were
considered reliable if the relative SE of the estimate was less than 30%.
The limitations imparted by CRS and AR were determined from the
presence of four specific dichotomous assessment variables within the
MEPS survey: activity limitation, work limitation, social limitation,
and cognitive limitation as reported by the patient. These limitation
variables have been validated and used previously to assess the
limitations associated with several chronic conditions including
asthma, diabetes, and rheumatoid arthritis. Differences in these func-
tional limitations were determined for those patients with and with-
out CRS and with and without AR, with a multivariate model that
adjusted for age, gender, race, ethnicity, education, insurance, region,
marital status, and Charlson comorbidity index score with statistical
significance set at p  .05.
RESULTS
The population demographics are presented in Table 1, encompass-
ing 225.1 million adults. The average age was 46.1  0.2 years. The
estimated prevalences of CRS and AR were 4.9  0.2% and 7.9 
0.3%, respectively (11.1  0.5 million and 17.8  0.7 million cases,
respectively). In Table 2 an analysis is presented of functional limita-
tions incrementally attributable to CRS for the study population.
Patients with CRS suffered from significant increased difficulties with
activity limitations, work limitations, and social limitations; there was
no identifiable cognitive limitation. CRS also was associated with an
incremental additional loss of 1.04  0.39 workdays per year relative
to those patients without CRS.
In Table 3 an analysis is presented of functional limitations in the
study population incrementally attributable to AR. AR was incremen-
tally associated with statistically significant increases in activity lim-
itation, work limitation, social limitation, and cognitive limitation for
affected adults. AR also was associated with an incremental addi-
tional loss of 0.60  0.45 workdays per year relative to those patients
without AR.
DISCUSSION
There is no question that both CRS and AR have significant foot-
prints in health care resource consumption in the United States.
Previous work has quantified the incremental per-patient, per-year
health care cost burdens of CRS and AR as $772 and $1492, respec-
tively.1,2 If patients’ CRS is severe enough to approach consideration
for surgery, yearly costs related to CRS may be even greater, ap-
proaching $2449.3 However, these figures examine the disease burden
primarily from the health care system’s vantage point.
The quality of life burdens and disease-specific quality of life bur-
dens of CRS and AR have been well quantified using various quality
of life assessment tools that measure the disease burden from the
patient’s standpoint.6–8 However, most of these studies have been
conducted in major academic institutions, often in tertiary care refer-
ral environments. For example, there are very little data available
regarding the quality of life burden due to CRS in the general pop-
ulation not already referred to otolaryngology. Naturally, those pa-
tients referred to otolaryngologists or rhinologists for a diagnosis of
CRS are likely to have more severe disease and thereby a higher
quality of life burden. The same likely holds true for AR. Therefore,
we sought to examine the functional limitations imparted by a diag-
nosis of CRS or AR at the population level to examine disease impact
on these elements of quality of life.
The functional limitations categorized herein as activity limitation,
work limitation, social limitation, and cognitive limitation are specific
queries within the MEPS construct. Although these are dichotomous,
self-reported assessments, they have been shown to have good reli-
ability and validity in several disease processes.10,12,13 Furthermore,
by using the incremental approach, adjusting for medical comorbidity
(with the Charlson comorbidity index) and demographic parameters,
we are better able to distill the individual impacts of CRS or AR on
these limitations.14 For example, it is well known that asthma may
accompany CRS and/or AR and influence the disease burden. How-
ever, the multivariate analysis controls for the presence of asthma
(and its potential impact on these limitations, etc.) through the Charl-
son comorbidity index as a covariate.
It is not surprising that both CRS and AR are associated with
significant activity and work limitations. Previous publications have
identified a substantial increase in workdays missed due to CRS,
which is often remediated after endoscopic sinus surgery.15,16 The
social limitations associated with CRS and AR may be more complex
in nature. Patients often report social embarrassment related to con-
stant rhinorrhea, sneezing, purulent discharge, or vocal congestion in
the setting of CRS or AR.7 In addition, smell disturbances associated
with these conditions may further compound social limitations.
One interesting variance between CRS and AR was that AR was
associated with a statistically significant odds of cognitive limita-
tion, whereas CRS was not. Anecdotally, patients have often re-
ported in the outpatient clinic various symptoms that resemble
cognitive limitations, such as their “head being in the clouds,”
difficulty concentrating, and early fatigue of mental capabilities in
the settings of both CRS and AR. The objective nature of these
symptoms is yet to be discerned. We have found previously that
even the nonsedating antihistamines have an increased rate of
patient-reported fatigue when used regularly.17 This is likely a
topic for future study.
Table 1 Demographics of study population
Variable % SE
Gender
Male 48.5 0.3
Female 51.5 0.3
Race
White 81.5 0.6
Black 11.5 0.5
Other 7.0 0.4
Ethnicity
Hispanic 13.5 0.6
Non-Hispanic 86.5 0.6
Highest degree
None 16.9 0.4
GED 3.8 0.2
High school diploma 44.8 0.5
Bachelors 17.5 0.4
Masters 6.6 0.3
Doctorate 2.2 0.2
Other 8.3 0.3
Marital status
Married 54.6 0.5
Not married 45.4 0.5
Health insurance
Private 69.6 0.5
Public 15.4 0.4
Uninsured 15.1 0.4
Census region
Northeast 18.7 0.7
Midwest 21.8 0.7
South 36.5 0.8
West 23.0 0.7
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level associated with CRS or AR deserves some scrutiny. Although on
average one or fewer days was missed in association with CRS or AR,
when evaluated at the population level this is a substantial figure.
Given the prevalence of CRS and AR, aggregate workdays missed in
the United States would be estimated as 11.5 million workdays and
10.7 million workdays for CRS and AR, respectively. These figures
further emphasize the substantial societal burden of these upper
respiratory diseases.
The use of the MEPS database for the study of disease impact has
been explored in several other conditions, including asthma, diabetes,
and spine/back problems, and it is widely felt to be reliable.14,18,19
However, several limitations of this database for the current study
merit mention. First, patients with CRS or AR were identified by a
International Classification of Diseases version 9 diagnosis code. This
methodology, in turn, depends on the accuracy of the diagnosis code
relative to the actual presence of CRS or AR. It is possible that
incorrect diagnosis codes were ascribed to patients not truly suffering
from CRS or AR; this may artificially inflate the perceived limitations
associated with these illnesses. A second limitation is that data for the
household component of the MEPS are completed by one household
member who may be a proxy, which may afford inaccuracies in
reporting. Survey data are subjected to postcollection checks for con-
sistency by survey administrators. Furthermore, the current method’s
linking of the household component to the medical provider compo-
nent (collected independently from the proxy household member)
serves as a secondary check for accuracy of reporting and code.
CONCLUSION
Both CRS and AR impart significantly increased odds ratios for
activity, work, and social limitations. CRS is associated with more
workdays lost than is AR. However, AR carries with it a statistically
significant odds ratio for functional cognitive limitation. Additional
work on a population-based scale will be required to better under-
stand the societal impact of these limitations in the setting of these
commonly prevalent conditions.
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Table 2 Functional limitations for patients with CRS
% Non-CRS patients SE % of CRS patients SE p Adjusted odds ratio* 95% CI
Activity limitation 11.7 0.3 13.3 1.4 .001 1.54 1.20–1.99
Work limitation 10.6 0.3 12.0 1.3 .005 1.50 1.13–1.98
Social limitation 7.2 0.2 9.0 1.0 .004 1.49 1.14–1.97
Cognitive limitation 6.2 0.2 6.0 0.8 .213 1.22 0.89–1.66
*Odds ratio adjusted for age, Charlson comorbidity index, gender, insurance, degree, region, marital status, and race and ethnicity.
Table 3 Functional limitations for patients with AR
% Non-AR patients SE % AR patients SE p Adjusted odds ratio* 95% CI
Activity limitation 11.4 0.3 15.3 1.1 .001 1.42 1.17–1.71
Work limitation 10.4 0.3 13.9 1.0 .001 1.43 1.18–1.73
Social limitation 7.0 0.2 10.4 0.9 .001 1.47 1.19–1.81
Cognitive limitation 6.1 0.2 7.7 0.7 .019 1.32 1.05–1.66
AR  allergic rhinitis.
*Odds ratio adjusted for age, Charlson comorbidity index, gender, insurance, degree, region, marital status, and race and ethnicity.
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